AJNN

The Academic Journal of Neurology and Neurosurgery deals with Neurology and Neurosurgery accepts articles on these topics. Academic Journal of Neurology and Neurosurgery publishes original research articles, review articles, case reports, editorial commentaries, letters to the editor, educational articles, and conference/meeting announcements.

EndNote Style
Index
Original Article
Evaluation of the relationship between thrombophilia gene mutations and demographic data, imaging findings and stroke subtypes in young patients followed up with a diagnosis of stroke
Aims: A stroke is defined as a focal or generalized neurological deficit that develops suddenly, lasts for more than 24 hours, or ends in death within this period, with a cause other than a vascular cause. Stroke is among the leading causes of morbidity and mortality in the general population. In our study, we examined the prevalence of all prothrombotic gene mutations observed in patients with and without predisposing risk factors for young patients with stroke and discussed their roles in stroke formation in the context of existing literature.
Methods: In the present study, we conducted a retrospective review of the medical records of 300 patients aged 18 to 49 years who were hospitalized in the neurology clinic of our hospital between June 2023 and June 2024 and diagnosed with acute arterial ischemic stroke based on anamnesis, neurological examination, and radiological imaging (CT and MRI) results. The study cohort comprised 47 patients (23 males, 24 females) aged between 18 and 49 years with a diagnosis of ischemic stroke. In our study, we examined ischemic stroke-related gene polymorphisms in patients with early-onset ischemic stroke (before the age of 50 years). This study aims to investigate the prevalence of Factor V-Leiden, prothrombin-G20210A, methylenetetrahydrofolate reductase (MTHFR) C677T, MTHFR A1298C, SERPIN 1, and Factor II polymorphisms in young patients with ischemic stroke.
Results: A total of 47 patients, comprising 23 males and 24 females, were included in the study. The mean age of the patients was 40.34 ± 6.37 years. According to the TOAST classification system, 17 patients (36.2%) were diagnosed with large artery atherothrombosis, one patient (2.1%) had a cardioembolic infarction, and 29 patients (61.7%) had a small artery occlusion. In our study, when evaluating the thrombophilia mutation subtypes in young ischemic stroke patients, 23.4% (n=11) of the patients were found to be heterozygous for the FVL mutation, while 76.6% (n=36) had no mutation. Concerning the SERPIN 1 mutation, 40.4% (n=19) of the patients were heterozygous, 23.4% (n=11) were homozygous, and 36.2% (n=17) exhibited no mutation. The distribution of patients according to MTHFR C677T mutation revealed that 57.4% (n=27) were heterozygous, 19.1% (n=9) were homozygous, and 23.4% (n=11) had no mutation. Considering the distribution of patients according to the MTHFR A1298C gene mutation, a total of 38.3% (n=18) of the patients were heterozygous, 14.9% (n=7) were homozygous, and 46.9% (n=22) had no mutation. Upon analysis of the distribution of patients according to factor XIII mutation, it was identified that 19.1% (n=9) were heterozygous, 2.1% (n=1) were homozygous, and 78.7% (n=37) of the patients exhibited no mutation. Upon analysis of the distribution of patients according to prothrombin (Factor II) mutation, it was identified that 8.5% (n=4) were heterozygous, while 91.5% (n=43) exhibited no mutation.
Conclusion: Although stroke is less prevalent in young adults, the underlying etiology is highly varied. Further research, including the investigation of genetic and prothrombotic mutations, is vital for the prevention of recurrent strokes in young adults.


1. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. <em>Lancet Neurol</em>. 2009;8(4):355-369.
2. Ekker MS, Verhoeven JI, Vaartjes I, Jolink WMT, Klijn CJM, de Leeuw FE. Association of stroke among adults aged 18 to 49 years with long-term mortality. <em>JAMA</em>. 2019;321(21):2113-2123.
3. Ekker MS, Boot EM, Singhal AB, et al. Epidemiology, aetiology, and management of ischaemic stroke in young adults. <em>Lancet Neurol</em>. 2018; 17(9):790-801
4. Nawaz B, Eide GE, Fromm A, et. al. Young ischaemic stroke incidence and demographic characteristics- The Norwegian stroke in the young study- Athree- generation research program. <em>Eur Stroke J</em>. 2019;4(4):347-354.
5. Marini C, Russo T, Felzani G. Incidence of stroke in young adults: a review. <em>Stroke Res Treat</em>. 2011;2011(1): 535672.
6. &Ouml;ncel &Ccedil;, Bir LS, Oğuzhanoğlu A, Er&ouml;z &Ouml;. Etiology of cerebrovascular disease in young adults. <em>J Neurol Sci</em>. 2009;26(1):12-17.
7. Bendixen BH, Posner J, Lango R. Stroke in young adults and children. <em>Curr Neurol Neurosci Rep.</em> 2001;1(1): 54-66.
8. Leys D, Bandu L, Henon H, et al. Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke. <em>Neurology</em>. 2002;59(1):26-33.
9. Feero WG. Genetic thrombophilia. <em>Prim Care</em>. 2004;31(3):685-709
10. Xin XY, Song YY, Ma JF, et al. Gene polymorphisms and risk of adult earlyonset ischemic stroke: a meta-analysis. Tromb Res. 2009;124(5):619-624.
11. Singhal AB, Biller J, Elkind MS, et al. Recognition and management of stroke in young adults and adolescents.<em>Neurology</em>. 2013;81(12):1089-1097. doi:10.1212/WNL.0b013e3182a4a451
12. Maaijwee NA, Rutten-Jacobs LC, Schaapsmeerders P, van Dijk EJ, de Leeuw FE. Ischaemic stroke in young adults: risk factors and long-term consequences. <em>Nat Rev Neurol</em>. 2014;10(6):315-325. doi:10.1038/nrneurol. 2014.72
13. Putaala J. Ischemic stroke in the young: current perspectives on incidence, risk factors, and cardiovascular prognosis.<em>Eur Stroke J</em>. 2016;1(1):28-40. doi: 0.1177/2396987316629860
14. Chiasakul T, De Jesus E, Tong J, et al. Inherited thrombophilia and the risk of arterial ıschemic stroke: a systematic review and meta-analysis. <em>J Am Heart Assoc</em>. 2019:8(19):e012877.
15. U&ccedil;ar F, S&ouml;nmez M, Ovali E, et al. MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population.<em>Am J Hematol</em>. 2004;76(1):40-43.
16. Li Z, Sun L, Zhang H, et al. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a Multicenter Case-Control Study in China.<em>Stroke</em>. 2003;34(9):2085-2090.
17. Fodinger M, Horl WH, Sunder-Plassman G. Molecular biology of 5,10- methylenetetrahydrofolate reductase. <em>J Nephrol</em>. 2000;13(1):20-33.
18. Alkanlı N. İskemik inmeli hastalrda calca, MTHFR gen polimorfizmleri ile plazma total homosistein d&uuml;zeylerinin araştırılması 2014:35-55
19. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies.<em>Am Heart J</em>. 2003;146(6):948-957.
20. Handin RI. Bleeding and thrombotic disorders In: Kasper DI, Braunwald E, Fauci AS, et al. Harrison&rsquo;s principles of internal medicine, 16th ed. New York, McGraw-Hill; 2005.p.277-8.
21. Friedline JA, Ahmad E, Garcia D, et al. Combined factor V leiden and prothrombin genotyping in patients presenting with thromboembolic episodes. <em>Arch Pathol Lab Med</em>. 2001;125(1):105-111.
22. Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. <em>J Thromb Haemost</em>. 2005;3(6):1213-1217.
23. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke.<em>Stroke</em>. 2000;31(1):26-32.
24. De Stefano V, Chiusolo P, Paciaroni K, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients.<em>Blood</em>. 1998;91(10):3562-3565.
25. Kaya H, Karkucak M, Salifoğlu H, Torun D, Kozan S, Tunca Y. Ven&ouml;z tromboembolili hastalarda anjiotensin d&ouml;n&uuml;ş- t&uuml;r&uuml;c&uuml; enzim I/D ve plazminojen aktivat&ouml;r-1 4G/5G gen polimorfizmlerinin araştırılması. <em>Tuberk Toraks</em>. 2013;61(2):88-95.
26. Rallidis LS, Megalou AA, Papageorgakis NH, Trikas AG, Chatzidimitriou GI, Tsitouris GK. Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction.<em>Thromb Haemost</em>. 1996;76(3):417-421.
27. Gonz&aacute;lez-Conejero R, Fern&aacute;ndez-Cadenas I, Iniesta JA, et al. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients.<em>Stroke</em>. 2006;37(9):2288-2293.
Volume 1, Issue 4, 2024
Page : 73-77
_Footer